COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN VERSUS RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION USING REAL-WORLD EVIDENCE IN MEDICARE BENEFICIARIES

被引：0
|
作者：
Peng, S. [1 ]
Deger, K. [1 ]
Ustyugova, A., V [2 ]
Gandhi, P. [3 ]
Qiao, N. [1 ]
Wang, C. [3 ]
Kansal, A. [1 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV61
引用
收藏
页码：A269 / A270
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China
    Liu, Lin
    Hong, Dongsheng
    Ma, Kuifen
    Lu, Xiaoyang
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (03) : 658 - 668
  • [22] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING
    Hori, M.
    Tanahashi, N.
    Akiyama, S.
    Kiyabu, G.
    Dorey, J.
    Goto, R.
    VALUE IN HEALTH, 2019, 22 : S554 - S555
  • [23] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [24] Persistence of Dabigatran Versus Warfarin Therapy in Patients with Non-valvular Atrial Fibrillation in the Real-world Clinical Practice
    Lau, Wallis C. Y.
    Chan, Esther W.
    Wong, Ian C. K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 382 - 382
  • [25] Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence)
    Anguita, Manuel
    Marin, Francisco
    Soto, Javier
    de Cabo, Susana Fernandez
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2025, 23 (1-2) : 45 - 51
  • [26] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [27] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [28] Characteristics and Clinical Outcomes of Patients Using Rivaroxaban Versus Dabigatran for Non-Valvular Atrial Fibrillation.
    Mahfouz, Ahmed
    Abu Yousef, Safae
    Hamou, Fatima
    Aljundi, Amer
    AlYafei, Sumaya
    Singh, Rajvir
    PHARMACOTHERAPY, 2018, 38 (04): : E31 - E31
  • [29] Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation
    Potpara, Tatjana S.
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (06) : 1093 - 1098
  • [30] Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review
    Deitelzweig, Steve
    Lip, Gregory Y. H.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (03) : 243 - 244
12345